AAAAAA

   
Results: 1-8 |
Results: 8
Introduction to the international human resource management special issue
Authors: Schneider, S Tung, R
Citation: S. Schneider et R. Tung, Introduction to the international human resource management special issue, J WORLD BUS, 36(4), 2001, pp. 341-345
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir- experienced subjects: AIDS Clinical Trials Group protocol 373
Authors: Gulick, RM Smeaton, LM D'Aquila, RT Eron, JJ Currier, JS Gerber, JG Acosta, E Sommadossi, JP Tung, R Snyder, S Kuritzkes, DR Murphy, RL
Citation: Rm. Gulick et al., Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir- experienced subjects: AIDS Clinical Trials Group protocol 373, J INFEC DIS, 183(5), 2001, pp. 715-721
Relationship of heart rate variability to parasympathetic effect
Authors: Goldberger, JJ Challapalli, S Tung, R Parker, MA Kadish, AH
Citation: Jj. Goldberger et al., Relationship of heart rate variability to parasympathetic effect, CIRCULATION, 103(15), 2001, pp. 1977-1983
The relentless march of the MOSFET gate oxide thickness to zero
Authors: Timp, G Bude, J Baumann, F Bourdelle, KK Boone, T Garno, J Ghetti, A Green, M Gossmann, H Kim, Y Kleiman, R Kornblit, A Klemens, F Moccio, S Muller, D Rosamilia, J Silverman, P Sorsch, T Timp, W Tennant, D Tung, R Weir, B
Citation: G. Timp et al., The relentless march of the MOSFET gate oxide thickness to zero, MICROEL REL, 40(4-5), 2000, pp. 557-562
Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir
Authors: Markland, W Rao, BG Parsons, JD Black, J Zuchowski, L Tisdale, M Tung, R
Citation: W. Markland et al., Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir, J VIROLOGY, 74(16), 2000, pp. 7636-7641
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)
Authors: Eron, JJ Smeaton, LM Fiscus, SA Gulick, RM Currier, JS Lennox, JL D'Aquila, RT Rogers, MD Tung, R Murphy, RL
Citation: Jj. Eron et al., The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850), J INFEC DIS, 181(5), 2000, pp. 1622-1628
Combined immunoprecipitation and agglutination for the detection of the heterodimeric molecule: Human chorionic gonadotropin as a study model
Authors: Tayapiwatana, C Tung, R
Citation: C. Tayapiwatana et R. Tung, Combined immunoprecipitation and agglutination for the detection of the heterodimeric molecule: Human chorionic gonadotropin as a study model, A P J ALLER, 17(4), 1999, pp. 301-306
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection
Authors: Murphy, RL Gulick, RM DeGruttola, V D'Aquila, RT Eron, JJ Sommadossi, JP Currier, JS Smeaton, L Frank, I Caliendo, AM Gerber, JG Tung, R Kuritzkes, DR
Citation: Rl. Murphy et al., Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection, J INFEC DIS, 179(4), 1999, pp. 808-816
Risultati: 1-8 |